EU/3/14/1259

Table of contents

About

On 8 April 2014, orphan designation (EU/3/14/1259) was granted by the European Commission to Insmed Limited, United Kingdom, for amikacin sulfate for the treatment of nontuberculous mycobacterial lung disease.

The sponsor’s address was updated in February 2019.

The sponsorship was transferred to Insmed Netherlands B.V., Netherlands, in February 2019.

Key facts

Active substance
Amikacin sulfate
Disease / condition
Treatment of nontuberculous mycobacterial lung disease
Date of decision
08/04/2014
Outcome
Positive
Orphan decision number
EU/3/14/1259

Sponsor's contact details

Insmed Netherlands B.V.
Building D Floor 4
Graadt Van Roggenweg 328-344
Utrecht
3531 AH
E-mail: tom.vanthienen@insmed.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating